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We constructed a double mutant version of the a sub-
unit of Go that was regulated by xanthine nucleotides
instead of guanine nucleotides (GoaX). We investigated
the interaction between GoaX and G protein-coupled
receptors in vitro. First, we found that the activated m2
muscarinic cholinergic receptor (MAChR) could facili-
tate the exchange of XTPgS for XDP in the GoaXbg het-
erotrimer. Second, the GoaXbg complex was able to in-
duce the high affinity ligand-binding state in the
N-formyl peptide receptor (NFPR). These experiments
demonstrated that GoaX was able to interact effectively
with G protein-coupled receptors. Third, we found that
the empty form of GoaX, lacking a bound nucleotide and
bg, formed a stable complex with the m2 muscarinic
cholingeric receptor associated with the plasma mem-
brane. Finally, we investigated the interaction of GoaX
with receptor in COS-7 cells. The empty form of GoaX
bound tightly to the receptor and was not activated
because XTP was not available intracellularly. We tested
the ability of GoaX to inhibit the activities of several
different G protein-coupled receptors in transfected
COS-7 cells and found that GoaX specifically inhibited
Go-coupled receptors. Thus the modified G proteins may
act as dominant-negative mutants to trap and inactivate
specific subsets of receptors.
Hundreds of seven-transmembrane receptors activate het-
erotrimeric G proteins and transduce signals across cell mem-
branes in eukaryotic cells. The stimulated receptors catalyze
the exchange of GTP for GDP bound to G protein a subunits.
Activated GTP-bound a subunits and free bg subunits regulate
a variety of cellular effectors including enzymes and ion-chan-
nels (1–3). Signaling is normally initiated by the binding of
agonist to receptor, which stabilizes the receptor in an active
conformation. Receptors function to stimulate the dissociation
of GDP bound to the G protein a subunits. The subsequent
binding of GTP to the empty a subunit promotes the conforma-
tional change of Ga and dissociation of the bg subunits. The G
protein a subunit in the nucleotide-free state appears to be an
important intermediate in the activation. From studies of rho-
dopsin and transducin, it has been postulated that the empty G
protein (nucleotide-free) forms a stable complex with the recep-
tor (4). Both empty forms of Gi and Go a subunits have been
purified under harsh conditions (1 M (NH4)2SO4 and 20% glyc-
erol), and they were unstable (5).
We recently reported that a mutant version of Goa, GoaX
(GoaD273N/Q205L), was regulated by xanthine nucleotides,
not by guanine nucleotides (6). GoaX bound XDP1 and XTP
instead of GDP or GTP. GoaX bound G protein bg subunits only
in the presence of XDP, and XTP stimulated dissociation of the
GoaXbg heterotrimer. XTP-bound GoaX underwent a confor-
mational change similar to the activated wild-type Goa. In the
present study, we investigated the interaction between GoaX
and G protein-coupled receptors. We found that GoaX mutant
proteins retained the receptor binding specificity of the wild-
type Goa and were able to interact with Go-coupled receptors,
such as the m2 muscarinic cholinergic receptor (MAChR), N-
formyl peptide receptor (NFPR), and thrombin receptor, but
not with m1 MAChR or thyrotropin-releasing hormone (TRH)
receptor which do not couple to wild-type Go. Because the
concentrations of XDP and XTP are relatively low in vivo (7),
GoaX mutant proteins are essentially nucleotide-free unless
exogenous xanthine nucleotides are provided. Thus, GoaX pro-
vides an excellent model to study the receptor interaction of
empty G protein a subunits. Consistent with the previously re-
ported studies on the empty form of transducin (4), our data are
most readily interpreted as showing that “empty” GoaX can form
a stable complex with appropriate receptors on the membrane.
EXPERIMENTAL PROCEDURES
Materials—Purified bovine retinal transducin bg were generous gifts
from Dr. O. Nakanishi (Division of Biology, Caltech). Xanthine and
guanine nucleotides were from Sigma. All the radioactive ligands in-
cluding [35S]ATPgS, [35S]GTPgS, [3H]QNB, and fML[3H]P were from
NEN Life Science Products.
Expression and Purification of His6-tagged Goa—Both wild-type Goa
and mutant GoaX were subcloned into the Escherichia coli expression
vector pET-15b (Novagen) with His6 tag at the N terminus. These
clones were used to transform the E. coli strain BL21(DE3), and pro-
teins were expressed. Expression and purification of these proteins was
described previously (6, 8). After harvesting the culture, cell extracts
were resuspended in the binding buffer (5 mM imidazole, 0.5 M NaCl,
160 mM Tris-HCl, pH 7.9, and 1 mM bMe). The His6-tagged proteins
were purified from Ni21-NTA column according to the protocol provided
by Novagen. Purified proteins were stored in TED buffer (20 mM Tris-
HCl, pH 8.0, 1 mM EDTA, and 1 mM dithiothreitol) with 0.1 mM MgCl2
and 0.1 mM nucleotide diphosphate (GDP or XDP as appropriate).
Membrane Preparation from Baculovirus-infected Sf9 Cells—Sf9
cells were grown and infected with recombinant baculoviruses encoding
either m2 MAChR or NFPR (9–11). Infected cells were centrifuged and
resuspended at ,107 cells/ml in HME/PI buffer (20 mM NaHepes, pH
8.0, 2 mM MgCl2, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 2
mg/ml aprotinin, and 10 mg/ml leupeptin). The cell suspension was
homogenized by 10 strokes in a glass homogenizer followed by passing
through a 27 gauge hypodermic needle several times. The homogenate
was briefly centrifuged at 3,000 3 g for 10 min, and then the superna-
tant was collected and centrifuged at 30,000 3 g for 30 min. The pellet
was washed once with HME/PI, and the final pellet was resuspended in
HME/PI at a protein concentration of 5 mg/ml.
Synthesis of XTPgS—XTPgS was synthesized from XDP and ATPgS
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1 The abbreviations used are: XDP, xanthine diphosphate; XTP, xan-
thine triphosphate; MAChR, muscarinic cholinergic receptor; NFPR,
N-formyl peptide receptor; TRH, thyrotropin-releasing hormone; NDK,
nucleotide diphosphate kinase; IP3, inositol 1,4,5-trisphosphate; PLC,
phospholipase C; GTPgS, guanosine 59-O-(3-thiotriphosphate); XTPgS,
xanthine 59-O-(3-thiotriphosphate); [3H]QNB, quinuclidinylbenzilate;
fML[3H]P, formyl-methionyl-leucyl-phenylalanine.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 273, No. 46, Issue of November 13, pp. 30183–30188, 1998
© 1998 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 30183
with nucleotide diphosphate kinase (NDK) as described previously (12).
To produce 35S-labeled XTPgS, the reaction contained 10 mM XDP, 1 mM
[35S]ATPgS, and 10 units of NDK (Sigma) in 100 ml of NDK buffer (1 mM
MgCl2, 5 mM dithiothreitol, and 20 mM Tris-HCl, pH 8.0). The mixture
was incubated at room temperature for 2 h. The resulting concentration
of [35S]XTPgS was about 1 mM (1 mCi/pmol). The radiochemical purity of
XTPgS was monitored by TLC on Avicel/PEAE plates (Analtech) in 0.07
N HCl.
Nucleotide Binding of Purified Goa—Binding of [35S]GTPgS and
[35S]XTPgS to the recombinant Goa or the mutant proteins was per-
formed as described (6). The binding reaction contained 0.5 mg of puri-
fied protein in TED buffer, with 0.1 mM MgCl2, 1 mM ATP, and 0.1 mM
GTPgS or XTPgS (20,000 cpm/pmol). For the time course experiments,
20-ml aliquots were withdrawn from a 200-ml reaction, diluted 10-fold
with ice-cold TED buffer containing 0.1 mM MgCl2, filtered through
45-mm nitrocellulose, washed, and dried. The amount of bound radio-
activity was determined by scintillation counting.
Radioligand Binding of Receptors—The ligand binding assays of
membrane-bound receptors were performed as described (9–11). The
total concentration of m2 MAChR and the affinities of NFPR were
determined by incubating membranes with 2 nM [3H]QNB or various
concentrations of fML[3H]P for 1 h in 20 mM Tris-HCl, pH 7.4, 12.5 mM
MgCl2, and 1 mM EDTA at 30 °C in a final volume of 0.5 ml. Nonspecific
binding was defined as binding that was not displaced by 10 mM atro-
pine for m2 MAChR or 10 mM fMLP for NFPR. Unbound ligands were
removed by filtration through Whatman GF/C filters and washing four
times using ice-cold binding buffer. The amount of bound radioactivity
was determined by scintillation counting.
Binding of Goa on Sf9 Cell Membranes—0.2 mg of purified Goa or
Goa mutant proteins were incubated with 100 mg of Sf9 cell membranes
in TED buffer of a final volume of 100 ml at room temperature for 1 h.
The membranes were centrifuged and subjected to Western blot using
antibodies against Goa.
Cell Culture and Transfection—COS-7 cells were cultured in Dulbec-
co’s modified Eagle’s medium containing 10% fetal calf serum. 1 3 105
cells/well were seeded in 12-well plates 1 day before transfection. All
transfection assays contained a total amount of 1 mg of DNA, and pCIS
encoding b-galactosidase was used to maintain a constant amount of
DNA. To each well, 1 mg of DNA was mixed with 5 ml of LipofectAMINE
(Life Technologies, Inc.) in 0.5 ml of Opti-MEM (Life Technologies, Inc.),
and 5 h later, 0.5 ml of 20% fetal calf serum in Dulbecco’s modified
Eagle’s medium was added to the medium. After 48 h, cells were
assayed for inositol phosphate levels as described previously (13, 14).
RESULTS
Stimulation of XTPgS Binding of GoaX by Activated M2
Muscarinic Receptor—To test if GoaX could interact with G
protein-coupled receptors, we investigated the receptor-stimu-
lated nucleotide binding of GoaX. Activated G protein-coupled
receptors are known to facilitate the binding of GTPgS to G
protein a subunits. It has been reported that recombinant m2
MAChR from Sf9 cells stimulated the binding of GTPgS to
wild-type Goa 2–3-fold in response to muscarinic agonists (9,
10). We infected Sf9 cells with recombinant baculoviruses en-
coding m2 MAChR and prepared membranes. The concentra-
tion of receptor was about 20 pmol/mg of membrane protein,
determined from [3H]QNB binding. We have previously shown
that GoaX mutant proteins bind only xanthine nucleotides, but
not guanine nucleotides. In this experiment, we reconstituted
purified GoaX with Sf9 cell membranes containing m2 MAChR
in the presence of XDP and G protein bg subunits purified from
bovine retina, and followed agonist-dependent stimulation of
XTPgS binding to GoaX. We found that carbachol accelerated
the XTPgS binding of GoaX, in a fashion similar to the accel-
eration of GTPgS binding observed with wild-type Goa (Fig.
1a). In control experiments using wild-type Sf9 cell mem-
branes, both atropine and carbachol had no effect on the XTPgS
binding of GoaX (Fig. 1a). bg subunits were required for the
carbachol-dependent stimulation of nucleotide binding (Fig.
1b), suggesting that only the trimeric complex of GoaX with bg
can be activated to exchange XDP for XTPgS by the ligand-
bound receptors.
High Affinity Ligand Binding of N-formyl Peptide Receptor
Induced by GoaX—Another well documented indication of re-
ceptor-G protein interaction is that GTP or GTPgS inhibits the
high affinity binding of G protein-coupled receptors to their
agonists. NFPR receptors expressed in Sf9 cells are known to
be in the low ligand affinity state (;60 nM fMLP) (11), presum-
ably because of the lack of mammalian Gi-like G proteins in Sf9
cells, whereas NFPR in neutrophils and NFPR expressed in
mouse L cells exhibited high affinity ligand binding (0.5–3 nM
fMLP) (15, 16). Therefore, we reconstituted GoaX with NFPR
from Sf9 cells and investigated whether GoaX could induce the
high affinity ligand binding state in NFPR receptors. Sf9 cell
membranes containing NFPR receptors were prepared as de-
FIG. 1. M2 MAChR stimulated XTPgS binding of GoaX. a, 0.5 mg
of purified GoaX was incubated with 1 mg of bg, 100 mg of m2 MAChR
membranes, or control Sf9 cell membranes and with 10 mM XDP in
TEDM buffer (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM dithiothre-
itol, and 1 mM MgCl2) for 30 min at room temperature, and then the
mixture was diluted 10-fold with TEDM buffer containing 0.1 mM
[35S]XTPgS (20,000 cpm/pmol) and 100 mM carbachol or 2 mM atropine
at time 0. 20-ml aliquots were withdrawn and assayed for the bound
nucleotides at the indicated times. b, 0.5 mg of purified wild-type Goa or
GoaX were subjected to the similar nucleotide binding assay as in panel
a with GTPgS or XTPgS under indicated conditions. Only data at 20
min were shown as the percentage of maximum binding.
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scribed under “Experimental Procedures.” The expression level
of NFPR was about 20 pmol/mg of membrane protein, deter-
mined by fML[3H]P binding. We incubated the NFPR with
wild-type Goa or mutant GoaX in the presence of bg and
varieties of nucleotides and determined their affinities for the
agonist fMLP. As expected, NFPR expressed in Sf9 cells
showed low ligand affinity binding of fMLP (;100 nM), and
GoaX alone did not affect ligand binding (Fig. 2a). More inter-
estingly, NFPR exhibited high affinity ligand binding (;10 nM)
when GoaX, bg, and XDP were present (Fig. 2a). Both bg and
XDP were required to induce the high ligand affinity state of
NFPR, and XTP inhibited the fMLP binding of the receptors
(Fig. 2b). In the control experiments, wild-type Go abg hetero-
trimer was also found to convert the NFPR to the high affinity
ligand binding state, which was inhibited by GTPgS (Fig. 2b).
These experiments demonstrated that the heterotrimeric com-
plex of GoaXbg can interact efficiently with NFPR.
Binding of GoaX with M2 Muscarinic Receptor on Sf9 Cell
Membranes—The previous two experiments showed that
GoaXbg heterotrimer could interact with the G protein-coupled
receptors efficiently and that the interaction was similar to the
interaction between wild-type Go and receptors. To investigate
receptor interaction of GoaX more directly, we studied binding
of GoaX to receptor containing Sf9 cell membranes. Purified
wild-type Goa or GoaX were incubated with Sf9 cell mem-
branes containing m2 MAChR in the presence of different
reagents. The membranes were then pelleted and subjected to
Western blotting using antibodies against Goa to see if Goa
remained bound to the membrane. In the control experiments
using wild-type Sf9 cell membranes without m2 MAChR, both
wild-type Goa and GoaX did not remain associated with the
membrane. However, wild-type Goa was bound to membrane
when it was coincubated with bg. Similarly, GoaX stayed on
the membrane when in complex with bg in the presence of XDP
(data not shown). These experiments using wild-type Sf9 cell
membranes showed that Goa bound to the membranes only in
the abg complex form, presumably because bg facilitates mem-
brane association. In the experiments using membranes con-
taining m2 MAChR, we found somewhat surprisingly that
GoaX bound to receptor-containing membranes even in the
absence of carbachol and without bg (Fig. 3, lane 12), whereas
wild-type Goa did not (Fig. 3, lane 1), suggesting GoaX alone
was able to bind to receptor. Interestingly, both XDP and XTP
abolished the interaction between GoaX and m2 MAChR-con-
taining membranes and released GoaX from the membrane
fraction (Fig. 3, lanes 7 and 8), whereas GDP or GTP had no
effect (data not shown), suggesting that the nucleotide-free
form of GoaX can recognize and bind to Go-mediated receptor.
As expected, GoaX stayed on the membrane when both XDP
and bg were present (Fig. 3, lane 10), and XTP promoted
dissociation of the GoaXbg complex (Fig. 3, lane 9). In the case
of wild-type Goa, the binding pattern was the same between
membranes with or without the receptors, and XDP or XTP had
no effect on binding (Fig. 3, lanes 1-5). In a titration experi-
ment, quantitation of GoaX revealed that the amount of GoaX
bound to the membrane increased linearly until it reached
saturation, and the level of saturation was proportional to the
amount of receptor incubated in the reaction (Fig. 4, a–c).
Furthermore, similar experiments using Sf9 cell membranes
containing NFPR were also performed, and the results were
similar (data not shown). These experiments indicated that the
empty form of GoaX, without a bound nucleotide and bg, could
form a stable complex with receptor. In summary, these data
FIG. 2. High affinity ligand binding of NFPR induced by GoaX.
a, 10 mg of NFPR membranes or wild-type Sf9 cell membranes were
incubated with various concentrations of fML[3H]P for 1 h in 20 mM
Tris-HCl, pH 7.4, 12.5 mM MgCl2, and 1 mM EDTA at 30 °C in a final
volume of 0.5 ml, in the presence of 0.1 mg of GoaX, 0.2 mg of bg, and 100
mM XDP, or GoaX alone. The amount of bound radioligand was then
determined. Nonspecific binding was defined as binding in the presence
of 10 mM cold fMLP, which was less than 10% of total ligand binding,
and was subtracted before analyzing. b, NFPR was incubated with 50
nM fML[3H]P and various reagents under the same conditions as panel a.
FIG. 3. Binding of GoaX to m2 MAChR on Sf9 cell membranes.
0.2 mg of wild-type Goa (with 100 mM GDP) or GoaX were incubated
with 100 mg of m2 MAChR membranes in TED buffer of a final volume
of 100 ml at room temperature for 1 h with indicated reagents. The
membrane then was centrifuged and subjected to Western blot using
antibodies against Goa. All nucleotide concentrations were 100 mM, and
the amount of bg was 0.5 mg. Lane 13 shows the total amount of Goa
used in each assay.
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suggest that GoaX with XDP bound and bg bind to membranes,
whereas the XTP form is found to be cytoplasmic. The nucle-
otide-free form is able to bind to Go-mediated receptors.
Dominant-negative Effect of GoaX on Receptor Activation in
COS-7 Cells—Because our experiments suggested that empty
GoaX was able to bind to the receptor in vitro, we went on to
test for this interaction in intact cells. Indeed, we found that
GoaX was able to interact with receptors and inhibit their
activities in COS-7 cells consistent with the observation that
GoaX did not dissociate from the receptors without xanthine
nucleotides. Thrombin receptors are known to couple with G
proteins from both the Gi and Gq families (17). In COS-7 cells
transfected with the thrombin receptor, endogenous Gq is ac-
tivated by the addition of thrombin and stimulates PLCb iso-
forms to elevate cellular IP3 concentration. Inhibition of recep-
tor activation in transfected cells by wild-type G proteins was
observed before (18). Thus if cells are cotransfected with both
the thrombin receptor and wild-type Goa subunit, the activa-
tion of Gq is inhibited because of the competition of Goa for the
receptor or endogenous G protein bg subunits (Fig. 5a). We
cotransfected thrombin receptor and GoaX to determine
whether GoaX could compete with endogenous Gq for the re-
ceptors. Indeed, we found that GoaX inhibited Gq activity
stimulated by thrombin, and the inhibition was proportional to
the amount of GoaX cDNA used in the transfection (Fig. 5a).
Because GoaX in the absence of XDP does not interact with bg
and does not affect the bg-stimulated PLCb activity in COS-7
cells (6), the inhibition by GoaX of Gq activation stimulated by
the thrombin receptor must come from the competitive binding
of GoaX to the receptor. Similar experiments were performed
with m1 MAChR and TRH receptor which were known to
couple only to the Gq family of Ga proteins and not to the Goa
family (10, 19, 20). GoaX had no effect on the activation of m1
MAChR or TRH receptor (Fig. 5, b and c). On the other hand,
wild-type Goa, which can compete for endogenous bg, inhibited
both m1 MAChR and TRH receptor stimulation as expected. In
COS-7 cells, the activation of thrombin receptor, m1 MAChR,
and TRH receptor share the same Gq pathway downstream of
the receptor. Because GoaX inhibited only the thrombin recep-
tor activity, but had no effect on m1 MAChR or TRH receptor,
we concluded that GoaX inhibited thrombin receptor stimula-
tion by competitive binding to the receptor.
To test if GoaX could bind to other Go-coupled receptors in
cells, we looked into the interaction between GoaX and m2
MAChR. Because m2 MAChR couples only to the Gi family of
Ga proteins and not to the Gq family (9, 21), we could not assay
their interaction in the same way as the thrombin receptor by
monitoring PLC activities in COS-7 cells transfected with the
receptor and GoaX. Therefore, we constructed an artificial
pathway by cotransfecting both m2 MAChR and G15a into
COS-7 cells. G15a is known as a promiscuous G protein that
can be activated by all kinds of G protein-coupled receptors,
and G15a also activates PLCb isoforms (21). In cells cotrans-
fected with both m2 MAChR and G15a, we were able to acti-
vate endogenous PLCb isoforms by the addition of the musca-
rinic agonist carbachol. We found that this m2 MAChR
stimulation pathway could also be inhibited by GoaX (Fig. 5d).
All these experiments suggested that GoaX was able to interact
with G protein-coupled receptors in cells and retained the re-
ceptor specificity of wild-type Goa; it coupled with thrombin
receptor and m2 MAChR, but not with m1 MAChR or TRH
receptor. Furthermore, GoaX exhibited dominant-negative in-
hibitory effects against these receptors in cells.
DISCUSSION
GoaX (GoaD273N/Q205L) was the first reported mutant of
heterotrimeric G protein a subunits that bound xanthine nu-
cleotides, not guanine nucleotides (6). It bound bg only in the
presence of XDP and could be activated by XTP. We continued
to study the interaction of GoaX with G protein-coupled recep-
tors in this report. The interaction of G proteins and their
receptors is best demonstrated in two experiments: agonist-
stimulated GTPgS binding of G protein a subunits and inhibi-
tion of high affinity ligand binding of the receptors by GTPgS.
To test if GoaX can interact with G protein-coupled receptors
and be activated by their agonists, we reconstituted purified
GoaX with Sf9 cell membranes containing m2 MAChR or
NFPR. First, we found that binding of XTPgS to GoaX was
stimulated by the muscarinic agonist carbachol in the presence
of m2 MAChR. In similar experiments using wild-type Goa,
GTPgS binding was also stimulated by carbachol. In both
cases, bg was required for the carbachol-dependent nucleotide
binding, suggesting that only GoaXbg heterotrimer could in-
teract with the receptors effectively. Second, we tested GoaX to
determine whether it could induce the high affinity state in
NFPR receptors expressed in Sf9 cells. The NFPR expressed in
these cells is known to be in the low affinity state probably
because of lack of mammalian Gi-like proteins in Sf9 cells (11).
In our experiments, we found that GoaX could convert NFPR
into the high affinity state in the presence of bg and XDP, and
this effect was inhibited by XTP. These two experiments dem-
onstrated that GoaX, when in complex with bg and XDP, could
interact with G protein-coupled receptors effectively and be
activated by the agonists.
Because cells lack xanthine nucleotides, GoaX provides an
excellent model to study empty G protein a subunits. The
empty form of Ga is an important intermediate in receptor
activation and has long been proposed to form a stable complex
with activated receptors. However stable interaction between
empty G proteins and their receptors was only reported in the
transducin-rhodopsin system. Empty transducin apparently
formed a stable complex with light-activated rhodopsin and
FIG. 4. Titration of GoaX bound to m2 MAChR on Sf9 cell
membranes. The binding assays were done under the same conditions
described in Fig. 3 legend. a, indicated amount of GoaX was incubated
with 100 mg of m2 MAChR membranes in TED buffer. b, the relative
intensities of bands in panel a were quantitated. c, quantitated binding
of 0.2 mg of GoaX with indicated amount of m2 MAChR membranes.
Wild-type Sf9 cell membranes were used to maintain a constant
amount of membranes of 200 mg in each binding reaction.
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stayed on the rod outer segment membrane. Interestingly,
deactivation of the rhodopsin did not lead to the dissociation of
transducin from the complex (4). In this report, we showed that
empty GoaX was able to bind to the receptor on the membrane
in the absence of bg subunits and without agonists, and the
interaction could be abolished by either XDP or XTP. The
amount of GoaX associated on the membranes with m2
MAChR was proportional to the amount of receptor at satura-
tion. Interestingly, binding of GoaX alone did not convert the
receptor to the high ligand affinity conformation, which re-
quired the abg complex. Therefore, the binding of GoaX alone
to the receptor is not functional in contrast with the binding in
the presence of bg and XDP.
Because GoaX appears to form a stable complex with the
receptor, we tested whether GoaX could inhibit receptor acti-
vation in cells. In transfected COS-7 cells, we showed that
GoaX was able to inhibit thrombin receptor or m2 MAChR
stimulated PLCb activities via the Gq or G15 pathway, but had
no effect on m1 MAChR or TRH receptor stimulation. Because
both thrombin receptor and m2 MAChR are known to couple
with wild-type Go, and m1 MAChR and TRH receptor only
couple with Gq, we interpret the data to mean that GoaX
retained the receptor specificity of wild-type Go and was able to
interact with Go-coupled receptors in cells. The inhibitory bind-
ing of GoaX enables us to specifically block Go-coupled recep-
tors in certain systems. This could be a useful means to analyze
FIG. 5. The negative inhibitory effects of GoaX on receptor-stimulated PLCb activation in COS-7 cells. 1 3 105 cells/well were seeded
in a 12-well plate and then were transfected with cDNAs encoding the indicated G proteins (GoaDN designates GoaD273N) and thrombin receptor
(a), m1 MAChR (b), TRH receptor (c), or m2 MAChR (d). In panels a–c, the amount of receptor cDNA used in each well was 0.25 mg, and the amount
of Goa cDNA was 0.75 mg/well unless otherwise indicated. In panel d, the amount of both m2 MAChR and G15a cDNA was 0.2 mg/well and that
of Goa was 0.6 mg/well. The total amount of cDNA for each well was adjusted to 1.0 mg by the addition of CMV-LacZ cDNA. After cells were labeled
with [3H]inositol overnight, they were incubated in the medium containing 0.1 unit/ml thrombin (a), 1 mM carbachol (b and d), or 1 mM TRH (c)
before levels of inositol phosphates were determined.
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different receptor-stimulated signal transduction pathways,
and could perhaps be useful in drug screening associated with
G protein-coupled receptors.
In the previous report (6), we showed that the single Goa
mutant, GoaD273N, lost the ability to bind either guanine
nucleotides or xanthine nucleotides and could not bind bg
under any conditions. Surprisingly, GoaD273N can still bind to
receptors. In transfected COS-7 cells, we found that GoaD273N
inhibited thrombin receptor and m2 MAChR activation, in a
fashion similar to GoaX (Fig. 5, a and d). GoaD273N also
retained the same receptor specificity as wild-type Goa; i.e. it
had no effect on m1 MAChR or TRH receptor stimulated path-
ways (Fig. 5, b and c). In the Sf9 cell membrane binding assay,
it only bound to the m2 MAChR membranes, not to the control
wild-type Sf9 cell membranes. However in contrast to GoaX,
GoaD273N was not released from the m2 MAChR membranes
by XDP or XTP, consistent with its inability to bind nucleotides
(data not shown). The reason that GoaD273N mutant proteins
do not bind xanthine nucleotides is not clear. Apparently it
must have a structure similar to that of the empty Goa which
enables it to bind receptors, but the structure is probably not
stable locally around the nucleotide binding pocket. Neverthe-
less, GoaD273N may also be useful as a dominant-negative
inhibitor of receptor functions.
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